Latest Investment Activity News

Page 2 of 57
Orbminco has completed the main technical studies for its Majestic North gold project, confirming free-milling ore and a potential low-capital Stage 1 route. The next hurdle is financial: the company held A$697,000 at quarter-end, equivalent to 0.59 quarters of reported funding.
Maxwell Dee
Maxwell Dee
30 Oct 2026
Xenitra has returned to positive quarterly gross profit as its new pharmaceutical and Web3 businesses begin generating revenue, but statutory operating cash flow remained negative at A$790,000. The company is now relying on procurement targets, repeat Web3 sales and further capital discipline to turn early commercial activity into sustainable cash generation.
Victor Sage
Victor Sage
30 Oct 2026
North Stawell Minerals has extended its Darlington gold system and sharpened its exploration focus, but the annual report carries a material uncertainty over the company’s ability to continue as a going concern. Cash fell to $701,960 as the explorer’s annual loss widened to $1.24 million.
Maxwell Dee
Maxwell Dee
30 Oct 2026
Citigold has identified four priority exploration targets at Charters Towers, but no drilling was completed during the September quarter and its reported cash runway fell below half a quarter. The company is also heading into two meetings seeking to replace its board as it pursues funding for the mine restart.
Maxwell Dee
Maxwell Dee
30 Oct 2026
Prominence Energy has expanded its South Australian exploration story from a single project to a portfolio with more than 4 Tscf of gross unrisked 2U hydrogen prospective resources. The company is targeting a multi-well drilling campaign in mid-2027, but its A$1.38 million cash balance leaves funding and permitting as important hurdles.
Maxwell Dee
Maxwell Dee
30 Oct 2026
Renascor Resources has produced battery-grade purified spherical graphite at 99.97% carbon purity from its Adelaide demonstration facility, strengthening technical validation of its HF-free process. The result came from third-party material, leaving Siviour graphite trials, customer qualification and project financing as the next tests.
Maxwell Dee
Maxwell Dee
30 Oct 2026
Metgasco’s September quarter delivered lower production and revenue, while unrestricted cash covered less than one quarter of operating needs. The company is pursuing recapitalisation as A$7.3 million of debt approaches a December maturity and 30.15 PJe of reserves shifts into contingent resources.
Victor Sage
Victor Sage
30 Oct 2026
Terragen has completed the induction of 10,600 cattle into its largest feedlot trial and secured Brazilian approval for its probiotic feed additive. But customer receipts fell to $255,000 for the September quarter, while cash declined to $5.73 million amid a CEO departure and chair transition.
Ada Torres
Ada Torres
30 Oct 2026
Arrow Minerals is rapidly expanding its Pilbara footprint, with 13 new exploration applications covering about 979 square kilometres and a post-quarter-end deal for the Turee Creek project. The company also resumed work at its Niagara bauxite project in Guinea, but entered the next phase with $2.02 million in cash and an estimated 2.3 quarters of funding at its reported operating cash-use rate.
Maxwell Dee
Maxwell Dee
30 Oct 2026
Volt Resources has secured US$5.4 million in fully funded support for its Alabama graphite strategy, but ended the September quarter with only A$170,000 in cash. The company is also managing lower-than-planned Ukrainian production, cancelled Tanzanian mining licences and a partly conditional A$1.5 million capital raising.
Victor Sage
Victor Sage
30 Oct 2026
Raptor Metals has completed its first Chester drilling campaign, with broad copper intersections and electromagnetic conductors pointing to follow-up targets across the Canadian project. The company is now preparing 2,800 metres of maiden drilling at Silverjack and Turgeon while holding $1.325 million in cash.
Maxwell Dee
Maxwell Dee
30 Oct 2026
Ceretas has enrolled the first patient in its Phase 2 CERE-CALM Alzheimer’s trial after completing its first quarter as an ASX-listed company. The medical technology group ended September with $7.1 million in cash, while a device milestone unlocked a further $692,578 in non-dilutive funding.
Victor Sage
Victor Sage
30 Oct 2026

Browse the archive

Full archive